SiRNA RSS

Filtered By:
Specialty: Cancer & Oncology
Cancer: Prostate Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 286 results found since Jan 2013.

PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Authors: Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, have shown treatment efficacy in BRCA1/2-deficient tumors. However, since PARP inhibitors (PARPi) mainly modulate the activation of PARP but not its expression, whether small interfering RNA (siRNA) specific to PARP has the same function as PARPi has not been well defined. In the present study it was demonstrated that PARP1-siRNA could reduce prostate cancer (PCa) cell progression regardless of the BRCA1/2 mutation. PARP1 silencing could significantly inhibi...
Source: Oncology Reports - February 4, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer.
CONCLUSIONS: LNP siRNA can silence target genes in vivo and enable inhibition of traditionally non-druggable genes like CLU and other promising co-targeting approaches in ENZ-R CRPC therapeutics. PMID: 26106075 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 23, 2015 Category: Cancer & Oncology Authors: Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave ME Tags: Clin Cancer Res Source Type: research

A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.
Abstract Specific and efficient delivery of siRNA into intended tumor cells remains as a challenge, even though RNAi has been exploited as a new strategy for prostate cancer therapy. This work aims to address both specificity and efficiency of SURVIVIN-siRNA delivery by constructing a therapeutic complex using combinatorial strategies. A fusion protein STD was first expressed to serve as a backbone, consisting of streptavidin, a cell-penetrating peptide called Trans-Activator of Transcription (TAT) and a double-stranded RNA binding domain. A biotinylated Prostate Specific Membrane Antigen (PSMA) specific aptamer A...
Source: Cancer Biology and Therapy - March 8, 2016 Category: Cancer & Oncology Authors: Diao Y, Liu J, Ma Y, Su M, Zhang H, Hao X Tags: Cancer Biol Ther Source Type: research

Abstract 3948: Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells
Conclusion: We identified a new chaperone harbouring an enzymatic activity which could be a relevant therapeutic target in chemoresistant CRPC. We are now focusing on the identification of a specific inhibitor in order to validate the role of this target in two Docetaxel-resistant prostate cancer mice models established within the laboratory.Citation Format: Marine Garrido, Nicolas J-p Martin, Catherine Gaudin, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Karim Fizazi, Anne Chauchereau. Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-res...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Garrido, M., Martin, N. J.-p., Gaudin, C., Del Nery, E., Camonis, J., Perez, F., Lerondel, S., Le Pape, A., Fizazi, K., Chauchereau, A. Tags: Molecular and Cellular Biology Source Type: research

Small extracellular vesicle-mediated < em > ITGB6 < /em > siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biol Ther. 2022 Dec 31;23(1):173-185. doi: 10.1080/15384047.2022.2030622.ABSTRACTThe αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased in metastatic castrate-resistant androgen receptor-negative prostate tumors compared to androgen receptor-positive prostate tumors. In addition, the αVβ6 integrin protein levels are significantly elevated in androgen receptor-negative PrC...
Source: Cancer Biology and Therapy - February 21, 2022 Category: Cancer & Oncology Authors: Shiv Ram Krishn Vaughn Garcia Nicole M Naranjo Fabio Quaglia Christopher D Shields Maisha A Harris Andrew V Kossenkov Qin Liu Eva Corey Dario C Altieri Lucia R Languino Source Type: research

Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the alphaVbeta6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biol Ther. 2022 Dec 31;23(1):173-185. doi: 10.1080/15384047.2022.2030622.ABSTRACTThe αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased in metastatic castrate-resistant androgen receptor-negative prostate tumors compared to androgen receptor-positive prostate tumors. In addition, the αVβ6 integrin protein levels are significantly elevated in androgen receptor-negative PrC...
Source: Cancer Control - February 21, 2022 Category: Cancer & Oncology Authors: Shiv Ram Krishn Vaughn Garcia Nicole M Naranjo Fabio Quaglia Christopher D Shields Maisha A Harris Andrew V Kossenkov Qin Liu Eva Corey Dario C Altieri Lucia R Languino Source Type: research

Abstract B166: A RNA helicase siRNA screen to identify potential therapeutic targets in castration-resistant prostate cancer
Castration-resistant prostate cancers (CRPC) are resistant to androgen-deprivation therapies commonly used to treat carcinoma of the prostate, resulting in death from this disease. CRPC can remain AR-driven through upregulation of the expression of wild-type, mutated or alternatively spliced constitutively active AR. Targeting both full-length AR and AR splice variants may overcome endocrine resistance. Since RNA helicases play crucial roles in various aspects of RNA metabolism including transcription, pre-mRNA splicing, translation, RNA export and RNA decay, we evaluated potentially druggable RNA helicases implicated in t...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Wang, H., de Billy, E., de Bono, J., Workman, P. Tags: Target Identification and Validation: Poster Presentations - Proffered Abstracts Source Type: research

Cancers, Vol. 12, Pages 3619: Advances in Targeting Cancer-Associated Genes by Designed siRNA in Prostate Cancer
Luo Short interfering RNAs (siRNAs) have provided novel insights into the field of cancer treatment in light of their ability to specifically target and silence cancer-associated genes. In recent years, numerous studies focus on determining genes that actively participate in tumor formation, invasion, and metastasis in order to establish new targets for cancer treatment. In spite of great advances in designing various siRNAs with diverse targets, efficient delivery of siRNAs to cancer cells is still the main challenge in siRNA-mediated cancer treatment. Recent advancements in the field of nanotechnology and nanomedicin...
Source: Cancers - December 3, 2020 Category: Cancer & Oncology Authors: Amirhossein Bahreyni Honglin Luo Tags: Review Source Type: research

Silencing of hepsin and inosine 5-monophosphate dehydrogenase 2 by siRNA reduces prostate cancer cells proliferation
This study aimed to determine the transcript level of PCa-related genes, HPN and IMPDH2, in archived tissues. Their functional roles were further determined using an in vitro model of PCa. Total RNA extraction was done from formalin-fixed paraffin-embedded PCa tissues, and benign prostatic hyperplasia (BPH) tissues acted as the control. Quantitative real-time polymerase chain reaction (qPCR) was performed to measure HPN and IMPDH2 expression. The functional assay was performed in a prostate cancer cell line (DU145) on these two genes by silencing their RNA. We discovered a significantly higher expression of IMPDH2 in PCa s...
Source: Cancer Control - April 29, 2022 Category: Cancer & Oncology Authors: N A Wahab H D Dardar R Yunus Z M Zainudin N M Mokhtar Source Type: research

Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA
Highlights: Abstract: Prostate cancer urgently needs an efficient therapy. Here we demonstrated that cisplatin combined with gene therapy by transfecting the attenuated Salmonella that carry a plasmid containing p53 gene and MDM2 siRNA provided a super-synergistic effect on the inhibition of prostate cancer growth in vivo. This synergistic therapy was associated with the induction of apoptotic cell death with a decreased Bcl2 to Bax expression ratio and increased expression of cleaved caspase 3 and caspase 9 in the prostate cancer xenograft. These results indicate that cisplatin-chemotherapy in combination with targeting t...
Source: Cancer Letters - June 21, 2013 Category: Cancer & Oncology Authors: Tao Jiang, Changdong Zhou, Junlian Gu, Yanan Liu, Lijing Zhao, Wei Li, Guanjun Wang, Yang Li, Lu Cai Tags: Research Articles Source Type: research

PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth
Abstract: The down-regulation of Notch1 by small interfering RNA (siRNA) can significantly inhibit human prostate cancer cell growth. The delivery of siRNA into specific cells is a key requirement for its clinical application. Recent reports have indicated that antibody-mediated siRNA delivery is an effective approach for targeted knockdown of specific genes in appropriate cells. Prostate-specific membrane antigen (PSMA) is regarded as an ideal target for the delivery of therapeutic agents to prostate cancer cells. The purpose of the present study was to evaluate whether siRNA can be efficiently delivered into PSMA-positiv...
Source: Cancer Letters - July 1, 2013 Category: Cancer & Oncology Authors: Yansheng Su, Liang Yu, Na Liu, Zhangyan Guo, Guodong Wang, Jia Zheng, Ming Wei, He Wang, An-gang Yang, Weijun Qin, Weihong Wen Tags: Research Articles Source Type: research

Abstract 4590: Cisplatin-RNAi nanotherapeutics for synergistic anti-tumor activity
Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, the development of acquired chemoresistance is a persistent clinical problem limiting the successful treatment of malignancies and considerable work has been done to identify the molecular mechanisms involved. Many possible mechanisms have been suggested for platinum resistance emergence, such as drug efflux, apoptosis inhibition among others. Recent studies have shown that the suppression of crucial gene products (e.g. REV1, REV3L) involved in the error-prone translesion DNA synthesis pathway can sensitiz...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Xu, X., Zhang, X., Xie, K., Walker, G., Farokhzad, O. Tags: Experimental and Molecular Therapeutics Source Type: research

Loading of "cocktail siRNAs" into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer
Cancer Biol Ther. 2022 Dec 31;23(1):163-172. doi: 10.1080/15384047.2021.2024040.ABSTRACTExtracellular vesicles (EVs) are cell-derived, membranous nanoparticles that mediate intercellular communication by transferring biomolecules between cells. As natural vehicles, EVs may exhibit higher delivery efficiency, lower immunogenicity, and better compatibility than existing RNA carriers. A major limitation of their therapeutic use is the shortage of efficient, robust, and scalable methods to load siRNA of interest. Here, we report a novel strategy using polycationic membrane-penetrating peptide TAT to encapsulate siRNAs into EVs...
Source: Cancer Biology and Therapy - February 16, 2022 Category: Cancer & Oncology Authors: Yanjun Diao Gangqiang Wang Bingbing Zhu Zhuo Li Shan Wang Lijuan Yu Rui Li Weixiao Fan Yue Zhang Lei Zhou Liu Yang Xiaoke Hao Jiayun Liu Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20